Skip to content
Screener

Recursion Pharmaceuticals, Inc. RXRX Q2 2025 earnings

Reported August 5, 2025 · Before market open

Revenue$19.1MMiss by $822.0K
EPS-$0.41Miss by $0.06
Revenue estimate$19.9M
EPS estimate-$0.35

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$14.2M
EPS estimate-$0.24

Financials

Q2 2025

Income statement

See full
Revenue$19.2M+33.3%
Gross profit-$938.0K-118%
Operating income-$176.2M-75.3%
Net income-$171.9M-76.2%
EPS (diluted)-$0.41-2.5%

Balance sheet

See full
Cash & equivalents$533.8M+10.6%
Total debt$110.7M-7.6%
Total equity$919.1M+57.3%
Total assets$1.3B+67.9%

Cash flow

See full
Operating cash flow-$76.4M+7.1%
CapEx$3.2M+166%
Free cash flow-$79.6M+4.6%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$2.12B+16.8%
Enterprise value$1.7B+16.9%
P/S32.8×-3.7×

Profitability

See full
Operating margin-1,005.8%+358pp
Net margin-1,004.9%+496pp
FCF margin-609.7%-63.1pp

Returns & leverage

See full
Return on equity-86.3%+23.4pp
Debt / equity0.1×-0.1×
Current ratio3.6×-2.5×

Segments

By product

See full
Operating revenue$19.1M+32.6%
Grant revenue$120.0K+823%

By segment

See full
Reportable Segment$19.2M+33.3%

By geography

See full
Other--100%

FAQ

When did Recursion Pharmaceuticals, Inc. report Q2 2025 earnings?
Recursion Pharmaceuticals, Inc. (RXRX) reported Q2 2025 earnings on August 5, 2025 before market open.
What were Recursion Pharmaceuticals, Inc.'s Q2 2025 revenue and EPS?
Recursion Pharmaceuticals, Inc. reported revenue of $19.1M and eps of $-0.41 for Q2 2025.
Did Recursion Pharmaceuticals, Inc. beat estimates in Q2 2025?
Revenue missed the consensus estimate of $19.9M by $822.0K. EPS missed the consensus estimate of $-0.35 by $0.06.
How did Recursion Pharmaceuticals, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 32.5% from $14.4M a year earlier and eps declined 2.5% from $-0.40.
Where can I find Recursion Pharmaceuticals, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001601830-25-000126) and the 10-Q periodic report (0001601830-25-000127) directly on SEC EDGAR. The filing index links above go to sec.gov.